Definitions

from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. A monoclonal antibody being developed for the treatment of type 1 diabetes and other autoimmune diseases.

Etymologies

from Wiktionary, Creative Commons Attribution/Share-Alike License

-li- +‎ -xi- +‎ -zu- +‎ -mab

Examples

  • The drug, called otelixizumab, was previously used in much stronger doses to prevent transplant patients rejecting donor organs.

    Latest news, breaking news, current news, UK news, world news, celebrity news, politics news

  • Research team hopes that the drug, called otelixizumab, will turn off this response by the immune system, placing the patient into remission for years and potentially forever.

    The Times of India

  • *** Pharmaceuticals GlaxoSmithKline and U.S. partner Tolerx said their experimental drug otelixizumab failed to achieve its target in a late-stage clinical trial for Type 1 diabetes.

    Business Watch

  • Louise Makin , BTG's chief executive, said in a statement that "the result of the DEFEND-1 study is obviously disappointing, though we note that Glaxo is continuing development of otelixizumab in autoimmune diseases."

    Glaxo's BTG Drug Fails to Pass Trial

  • Tolerx is responsible for the clinical and regulatory activities for otelixizumab in Type 1 diabetes in the U.S. and has the option to jointly promote otelixizumab in Type 1 diabetes in the U.S. with Glaxo, while the U.K. drug maker has exclusive rights to develop and commercialize otelixizumab in all other indications in the rest of the world.

    Glaxo's BTG Drug Fails to Pass Trial

  • Glaxo and Tolerx set up an alliance in October 2007 to develop and commercialize otelixizumab for a range of autoimmune and immune-mediated inflammatory diseases, including Type 1 diabetes.

    Glaxo's BTG Drug Fails to Pass Trial

  • LONDON— GlaxoSmithKline PLC and its U.S. partner Tolerx Inc. Friday said their experimental drug otelixizumab failed to pass a late-stage clinical trial for Type 1 diabetes.

    Glaxo's BTG Drug Fails to Pass Trial

  • The two companies in a joint statement said otelixizumab, an investigational anti-CD3 monoclonal antibody for treating adults with newly diagnosed Type 1 diabetes, didn't meet the primary endpoint set for a Phase III study named DEFEND-1.

    Glaxo's BTG Drug Fails to Pass Trial

  • Separately, Glaxo said it signed a deal with U.S. biotechnology company Tolerx Inc. to develop otelixizumab, a diabetes drug.

    Glaxo and Mylan Settle

  • During the trial patients will receive a one-off dose of otelixizumab, administered intravenously for between two and five hours a day over five consecutive days.

    Latest news, breaking news, current news, UK news, world news, celebrity news, politics news

Comments

Log in or sign up to get involved in the conversation. It's quick and easy.